AMT-562 also improved TGI in CRC cell line xenografts compared with HER3-DXd and Ab562-GGFG-DXd, demonstrating improved tumor-killing capacity conferred by Ab562 over patritumab [132]. Here, ERBB3 is linked to neoplasm.